Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIX NASDAQ:ENTA NASDAQ:IPSC NASDAQ:NGNE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.03+1.0%$2.84$2.44▼$5.46$100.58M0.64120,044 shs125,870 shsENTAEnanta Pharmaceuticals$15.46+0.8%$13.64$5.03▼$17.15$445.16M1.01144,015 shs298,487 shsIPSCCentury Therapeutics$2.29$2.33$0.44▼$3.04$413.01M1.55872,160 shs807,000 shsNGNENeurogene$30.89+0.4%$23.48$13.93▼$37.27$480.65M1.69192,365 shs116,644 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences0.00%-4.46%+11.52%+0.67%+14.94%ENTAEnanta Pharmaceuticals0.00%+6.90%+8.72%+10.92%+191.08%IPSCCentury Therapeutics0.00%-0.87%+1.78%+17.44%+326.44%NGNENeurogene0.00%+14.60%+50.98%+74.63%+110.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.03+1.0%$2.84$2.44▼$5.46$100.58M0.64120,044 shs125,870 shsENTAEnanta Pharmaceuticals$15.46+0.8%$13.64$5.03▼$17.15$445.16M1.01144,015 shs298,487 shsIPSCCentury Therapeutics$2.29$2.33$0.44▼$3.04$413.01M1.55872,160 shs807,000 shsNGNENeurogene$30.89+0.4%$23.48$13.93▼$37.27$480.65M1.69192,365 shs116,644 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences0.00%-4.46%+11.52%+0.67%+14.94%ENTAEnanta Pharmaceuticals0.00%+6.90%+8.72%+10.92%+191.08%IPSCCentury Therapeutics0.00%-0.87%+1.78%+17.44%+326.44%NGNENeurogene0.00%+14.60%+50.98%+74.63%+110.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIXAnixa Biosciences 2.25Hold$8.50180.53% UpsideENTAEnanta Pharmaceuticals 2.75Moderate Buy$20.2931.21% UpsideIPSCCentury Therapeutics 2.43Hold$4.2585.59% UpsideNGNENeurogene 2.75Moderate Buy$67.00116.90% UpsideCurrent Analyst Ratings BreakdownLatest ANIX, NGNE, IPSC, and ENTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2026NGNENeurogene GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$69.004/28/2026NGNENeurogene GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026NGNENeurogene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026IPSCCentury Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.00 ➝ $5.004/20/2026ENTAEnanta Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026ANIXAnixa Biosciences D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.004/6/2026IPSCCentury Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/6/2026NGNENeurogene Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$180.003/31/2026ANIXAnixa Biosciences D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/26/2026ENTAEnanta Pharmaceuticals Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.003/13/2026IPSCCentury Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetMarket Perform$2.00(Data available from 5/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIXAnixa Biosciences$210K483.79N/AN/A$0.42 per share7.21ENTAEnanta Pharmaceuticals$65.32M6.87N/AN/A$3.03 per share5.10IPSCCentury Therapeutics$109.16M3.78$0.01 per share172.18$1.82 per share1.26NGNENeurogene$930K518.82N/AN/A$17.10 per share1.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIXAnixa Biosciences-$10.93M-$0.33N/AN/AN/AN/A-70.95%-62.53%5/27/2026 (Estimated)ENTAEnanta Pharmaceuticals-$81.89M-$3.20N/AN/AN/A-106.80%-78.58%-23.18%5/11/2026 (Estimated)IPSCCentury Therapeutics-$9.58M-$0.14N/AN/AN/AN/A-1.43%-1.05%5/21/2026 (Estimated)NGNENeurogene-$90.35M-$4.24N/AN/AN/AN/A-32.99%-30.39%5/11/2026 (Estimated)Latest ANIX, NGNE, IPSC, and ENTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2026Q2 2026ANIXAnixa Biosciences-$0.10N/AN/AN/AN/AN/A5/21/2026Q1 2026IPSCCentury Therapeutics-$0.15N/AN/AN/A$2.87 millionN/A5/11/2026Q2 2026ENTAEnanta Pharmaceuticals-$0.46-$0.45+$0.01-$0.45$17.03 million$17.16 million5/11/2026Q1 2026NGNENeurogene-$1.2963N/AN/AN/AN/AN/A3/24/2026Q4 2025NGNENeurogene-$1.20-$1.12+$0.08-$1.12N/AN/A3/12/2026Q4 2025IPSCCentury Therapeutics-$0.29-$0.25+$0.04-$0.25($0.08) millionN/A3/9/2026Q1 2026ANIXAnixa Biosciences-$0.09-$0.08+$0.01-$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANIXAnixa BiosciencesN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIXAnixa BiosciencesN/A12.1812.18ENTAEnanta PharmaceuticalsN/A4.444.44IPSCCentury TherapeuticsN/A5.975.97NGNENeurogeneN/A16.5616.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIXAnixa Biosciences29.13%ENTAEnanta Pharmaceuticals94.99%IPSCCentury Therapeutics50.20%NGNENeurogene52.37%Insider OwnershipCompanyInsider OwnershipANIXAnixa Biosciences26.40%ENTAEnanta Pharmaceuticals11.48%IPSCCentury Therapeutics4.37%NGNENeurogene9.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIXAnixa Biosciences533.53 million24.68 millionOptionableENTAEnanta Pharmaceuticals16029.02 million25.69 millionOptionableIPSCCentury Therapeutics170180.35 million172.47 millionOptionableNGNENeurogene9015.62 million14.07 millionOptionableANIX, NGNE, IPSC, and ENTA HeadlinesRecent News About These CompaniesInsider Selling: Neurogene (NASDAQ:NGNE) CFO Sells $300,000.00 in StockMay 11 at 4:20 AM | americanbankingnews.comInsider Selling: Neurogene (NASDAQ:NGNE) CFO Sells 9,600 Shares of StockMay 9 at 6:43 AM | insidertrades.comNeurogene (NASDAQ:NGNE) CFO Christine Mikail Cvijic Sells 9,600 SharesMay 8 at 3:27 PM | marketbeat.comNeurogene (NASDAQ:NGNE) Trading 14.4% Higher - Still a Buy?May 6, 2026 | marketbeat.comNeurogene (NGNE) to Release Quarterly Earnings on ThursdayMay 6, 2026 | americanbankingnews.comWe Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business GrowthMay 5, 2026 | finance.yahoo.comJennison Associates LLC Increases Holdings in Neurogene Inc. $NGNEMay 3, 2026 | marketbeat.comNeurogene (NASDAQ:NGNE) Stock Rating Upgraded by GuggenheimMay 1, 2026 | marketbeat.comNeurogene (NGNE) Expected to Announce Quarterly Earnings on ThursdayApril 30, 2026 | marketbeat.comNeurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of "Moderate Buy" from AnalystsApril 29, 2026 | marketbeat.comNeurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene TherapyApril 28, 2026 | finance.yahoo.comNeurogene (NASDAQ:NGNE) Shares Up 0.1% - Here's What HappenedApril 28, 2026 | marketbeat.comNeurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of DirectorsApril 20, 2026 | businesswire.comNeurogene Inc.April 8, 2026 | edition.cnn.comNeurogene (NGNE) price target increased by 37.29% to 82.62March 27, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Neurogene (NGNE)March 26, 2026 | theglobeandmail.comNeurogene: Q4 Earnings SnapshotMarch 24, 2026 | finance.yahoo.comNeurogene Reports Full Year 2025 Financial Results and Highlights Recent UpdatesMarch 24, 2026 | businesswire.comNeurogene (NASDAQ:NGNE) CFO Sells $84,176.45 in StockMarch 18, 2026 | insidertrades.comNeurogene to Participate in Stifel 2026 Virtual CNS ForumMarch 11, 2026 | businesswire.comNeurogene: Stock Soars On FDA Designation For Rett Gene Therapy - I'd Remain CautiousFebruary 27, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 2026The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026NVIDIA's Quantum Computing Play Just Sent IonQ and Rigetti Flying By Jeffrey Neal Johnson | April 15, 2026From CrowdStrike to Chewy, These Tanking Stocks Are Announcing BuybacksBy Leo Miller | April 14, 2026ANIX, NGNE, IPSC, and ENTA Company DescriptionsAnixa Biosciences NASDAQ:ANIX$3.03 +0.03 (+1.00%) As of 04:00 PM EasternAnixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Enanta Pharmaceuticals NASDAQ:ENTA$15.46 +0.12 (+0.78%) Closing price 04:00 PM EasternExtended Trading$15.60 +0.14 (+0.91%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Century Therapeutics NASDAQ:IPSC$2.29 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.30 +0.01 (+0.44%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Neurogene NASDAQ:NGNE$30.89 +0.11 (+0.36%) Closing price 04:00 PM EasternExtended Trading$30.86 -0.04 (-0.11%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Meta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand Now Tapestry Stock Drops After Strong Quarter and Raised Outlook MarketBeat Week in Review – 05/04 - 05/08 Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
